주식/증권 ➡️ 중립 Daré Bioscience targets Ovaprene Phase III to reach 2,500 exposure cycles in 2026 as Flora Sync LF5 revenue is expected to begin in June Seeking Alpha - Market News 05/15/2026 01:42:13 AM 10회 원문 기사 보기